Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
activated donor lymphocyte infusion
- Development stage
- Phase 1
- Lead developer
- Abramson Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Activated donor lymphocyte infusion (ADLI) is an investigational cellular immunotherapy developed at the Abramson Cancer Center at Penn Medicine. The therapy involves the ex vivo expansion and activation of donor-derived T lymphocytes using anti-CD3 and anti-CD28 monoclonal antibody-coated beads. This costimulation process is designed to enhance the T cells' proliferative capacity and anti-tumor effector functions. ADLI is administered to patients with high-risk hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS), typically in a prophylactic setting following non-myeloablative allogeneic stem cell transplantation. The primary therapeutic goal is to augment the graft-versus-leukemia (GVL) effect to eliminate residual disease and prevent relapse while maintaining a manageable safety profile regarding graft-versus-host disease (GVHD).
- Other names
- prophylactic activated donor lymphocyte infusionCD3/CD28-activated donor lymphocyte infusionactivated DLIprophylactic activated DLI
Beyond the preview
Go deeper on activated donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on activated donor lymphocyte infusion.